Abeona Therapeutics Enters License for AAV Delivery Vector for FA Treatment

October 6, 2015

Abeona Therapeutics announces a license agreement with Stanford University for an AAV (adeno-associated virus) delivery vector for the treatment of Fanconi anemia and rare blood disease platform.